Novo Nordisk A/S (NVO) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Bagsvaerd, Denmark. The current CEO is Maziar Mike Doustdar.
NVO has IPO date of 1981-04-30, 77,406 full-time employees, listed on the New York Stock Exchange, a market capitalization of $174.74B.
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 that researches, develops, manufactures, and distributes medications globally across Europe, the Middle East, Africa, China, and North America. The company operates through two primary segments: Diabetes and Obesity Care, which offers treatments for diabetes, obesity, and cardiovascular conditions, and Rare Disease, which focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Beyond pharmaceutical products, Novo Nordisk provides delivery devices such as insulin pens and growth hormone pens, as well as digital health solutions including smart insulin pens and dose guidance applications. The company has established strategic collaborations with UNICEF on childhood obesity initiatives and with Valo Health to develop cardiometabolic therapies.
